Date

Company

Asset / Molecule

Regulatory Event

Impact

Mar 12

Eli Lilly

Lilly-Vax (LY345)

PDUFA Date (NSCLC)

High

Mar 18

Roche

Gantenerumab-X

Phase 3 Data Release

Critical

Mar 24

Vertex

VTX-901

FDA Priority Review

Medium

Mar 30

Novarex Tech

NRX-Bio07

S-GRAS Pending

Strategic